About
Alpenglow Biosciences is a 3D spatial biology company that utilizes AI-enabled 3D imaging technology to enhance drug development and clinical diagnostics. Founded in 2018 as a spinout from the University of Washington, the company rebranded in 2022 to reflect its growth and advanced technology offerings. The core technology platform, Aurora 3D™, digitizes entire tissue samples non-destructively, allowing for detailed spatial profiling and analysis. Alpenglow offers specialized assays such as the 3D Derm Score Assay™ for dermatology and the 3D I/O Pro Assay™ for immuno-oncology, which provide insights into skin tissue structures and tumor microenvironments, respectively. Their software tools, including the LUMI interface and m3D™ Automated Data Management, facilitate efficient data handling and analysis. Alpenglow collaborates with leading pharmaceutical companies to improve drug development processes and has received significant funding to support its research initiatives. The company is also partnering with ZEISS to develop advanced microscopy and bioinformatics solutions for clinical applications, aiming to enhance patient care through improved treatment recommendations.
Technologies
Keywords
Company Information
-
Employees 28
-
Founded 2018
-
Total Funding $8982788
Location
2121 North 35th Street, Seattle, Washington, United States, 98103
